Abstract
Abstract
Distributed network studies and multisite studies assess drug safety and effectiveness in diverse populations by pooling information. Targeting groups of clinical or policy interest (including specific sites or site combinations) and applying weights based on effect measure modifiers (EMMs) prior to pooling estimates within multisite studies may increase interpretability and improve precision. We simulated a 4-site study, standardized each site using inverse odds weights (IOWs) to resemble the 3 smallest sites or the smallest site, estimated IOW-weighted risk differences (RDs), and combined estimates with inverse variance weights (IVWs). We also created an artificial distributed network in the Clinical Practice Research Datalink (CPRD) Aurum consisting of 1 site for each geographic region. We compared metformin and sulfonylurea initiators with respect to mortality, targeting the smallest region. In the simulation, IOWs reduced differences between estimates and increased precision when targeting the 3 smallest sites or the smallest site. In the CPRD Aurum study, the IOW + IVW estimate was also more precise (smallest region: RD = 5.41% [95% CI, 1.03-9.79]; IOW + IVW estimate: RD = 3.25% [95% CI, 3.07-3.43]). When performing pharmacoepidemiologic research in distributed networks or multisite studies in the presence of EMMs, designation of target populations has the potential to improve estimate precision and interpretability.
This article is part of a Special Collection on Pharmacoepidemiology.
Publisher
Oxford University Press (OUP)
Reference37 articles.
1. Design of a national distributed health data network;Maro;Ann Intern Med.,2009
2. Confounding adjustment in comparative effectiveness research conducted within distributed research networks;Toh;Med Care.,2013
3. How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias;Platt;Pharmacoepidemiol Drug Saf.
4. Meta-analysis with sample-standardization in multi-site studies;Shu;Pharmacoepidemiol Drug Saf.,2023
5. The FDA Sentinel Initiative—an evolving national resource;Platt;N Engl J Med.,2018